EGFR and non-small cell lung carcinoma: A phase II trial (JO25567) conducted in Japan evaluated the efficacy and safety of first-line erlotinib plus bevacizumab versus erlotinib alone in nonsquamous NSCLC harboring mutant EGFR [76].